Thus, while AICAr pretreatment shields cardiomyocytes and sensitizes MCF7 cells to doxorubicin, the impact of AICAr on doxorubicin chemotherapeutic efficacy in other cancers will likely vary, depending upon ADK expression level, metabolic routes of AICAr or ZMP, and pre-existing p62/NRF2 expression in the targeted cancer cell type. The gene discussed is NFE2L2; the disease is cancer.